HER2-negative Breast Cancer Clinical Trials in Baltimore, Maryland

3 studies are recruiting for her2-negative breast cancer in Baltimore, Maryland right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

    This is a global, multicenter, open-label, randomized Phase 3 study comparing the efficacy and safety of RLY-2608 (zovegalisib) + fulvestrant to capivasertib + fulvestrant for the treatment of patients with HR+/HER2- ABC with PIK3CA mutation following recurrence or progression on or after treatment…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Sidney Kimmel Comprehensive Cancer Center (SKCCC) at Johns Hopkins, Baltimore, Maryland
    Locations
    231 in total
    Run by
    Relay Therapeutics, Inc.

    See if you can join NCT06982521 on ClinicalTrials.gov

  2. CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer

    This research study is being done to find out if the immunotherapy drugs called CDX-301 and CDX-1140 in combination with the standard chemotherapy treatment pegylated liposomal doxorubicin (PLD, Doxil) are safe and effective at controlling the cancer in patients with metastatic triple Human Epiderm…

    Stage
    Phase 1
    Ages
    18 to 99
    Site
    Johns Hopkins University, Baltimore, Maryland
    Locations
    7 in total
    Run by
    University of Texas Southwestern Medical Center

    See if you can join NCT05029999 on ClinicalTrials.gov

  3. A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer

    This is an adaptive Phase 2, open-label, randomized, multi-center study evaluating up to 2 regimens of PCS6422 with capecitabine (Cap) vs. standard dose of Cap alone in patients with advanced or metastatic breast cancer. The goal of the study is to assess the efficacy and safety of PCS6422 + Cap as…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    University of Maryland Medical Center (UMMC), Baltimore, Maryland
    Locations
    13 in total
    Run by
    Processa Pharmaceuticals

    See if you can join NCT06568692 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.